Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

IMPORTANCE: Agents targeting programmed cell death 1 (PD-1)/PD ligand 1 (PD-L1) improve long-term survival across many advanced cancers and are now used as adjuvant therapy for resected stage III and IV melanomas. The incidence and spectrum of chronic immune-related adverse events (irAEs) have not b...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:JAMA Oncol
Main Authors: Patrinely, J. Randall, Johnson, Rebecca, Lawless, Aleigha R., Bhave, Prachi, Sawyers, Amelia, Dimitrova, Maya, Yeoh, Hui Ling, Palmeri, Marisa, Ye, Fei, Fan, Run, Davis, Elizabeth J., Rapisuwon, Suthee, Long, Georgina V., Haydon, Andrew, Osman, Iman, Mehnert, Janice M., Carlino, Matteo S., Sullivan, Ryan J., Menzies, Alexander M., Johnson, Douglas B.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Medical Association 2021
נושאים:
Brief Report
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7995124/
https://ncbi.nlm.nih.gov/pubmed/33764387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2021.0051
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים